image: Cannabis and Cannabinoid Research is the only peer-reviewed open access journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. view more
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, May 8, 2018--A multidisciplinary panel of experts discussed how medicinal cannabis can impact the opioid crisis, though clinical research to quantify this is difficult given strict federal laws. The expert roundtable, titled "Cannabis and the Opioid Crisis," is published in Cannabis and Cannabinoid Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers . The article is available open access on theCannabis and Cannabinoid Research website.
Moderated by Daniele Piomelli, PhD, University of California, Irvine, School of Medicine and Editor-in-Chief of Cannabis and Cannabinoid Research, the panel discussion covered the legal and financial barriers to understanding how cannabis can be used to alleviate chronic pain and potentially ease the opioid crisis, as well as how state laws allowing medicinal cannabis have impacted the communities most affected by opioid use. Participants included Susan Weiss, National Institute on Drug Abuse; Graham Boyd, New Approach PAC, ACLU Drug Law Reform Project; Rosalie Liccardo Pacula, BING Center for Health Economics, Drug Policy Research Center, Pardee RAND Graduate School; and Ziva Cooper, Department of Psychiatry, Columbia University Medical Center.
"Is medicinal cannabis helpful or detrimental in the current opioid crisis? This deceptively simple question has no answer yet. Setting a research agenda to answer it is both important and urgent," says Editor-in-Chief Daniele Piomelli, University of California-Irvine, School of Medicine.
###
About the Journal
Cannabis and Cannabinoid Research is the only peer-reviewed open access journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. Led by Editor-in-Chief Daniele Piomelli, PhD, PharmD, the Journal publishes a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical, legal, and regulatory controversies. Complete information is available on the Cannabis and Cannabinoid Research website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Medicinal Food, The Journal of Alternative and Complementary Medicine, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Journal
Cannabis and Cannabinoid Research